Viking Therapeutics develops therapies to treat obesity. Several of its drug candidates showed promising data during phase 2 trials. With enough capital to complete phase 3 trials, the company's stock ...
Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 5 years by 32.8% on an annualized basis producing an average annual return of 46.0%. Currently, Viking Therapeutics has a ...
Five years ago, Viking Therapeutics (NASDAQ: VKTX) was an unknown, clinical-stage biotech. It hardly stood out in a sea of small drugmakers, and most of those never end up producing the kinds of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results